Progress Software (NASDAQ: PRGS) trades around $42, and the market appears to value it as a slow-growing legacy software company with leverage and acquisition risk. After digging through the business, I think that framing may miss the more interesting part of the story.
PRGS isn't really a high-growth SaaS play. Its organic ARR growth is only around 2%. The model is closer to a software roll-up: acquire mature recurring-revenue software assets, integrate them, improve margins, generate substantial FCF, deleverage, and repeat.
FY2026 guidance calls for roughly $1B of revenue, a \~39% non-GAAP operating margin, and $271–283M of adjusted FCF. I wouldn't value PRGS on its headline \~7x non-GAAP P/E because acquisition-related adjustments are substantial. The cash generation is the more interesting metric.
The next test is Domo. PRGS plans to pay $400M for Domo's core AI/data-platform operations, which generate roughly $318M in TTM revenue — only \~1.26x sales. Domo is distressed, but that's potentially the opportunity: PRGS gets data integration, BI, governance and AI-agent capabilities at a depressed valuation.
The possible mispricing is straightforward: the market is pricing PRGS primarily for low organic growth + leverage + legacy software risk, while potentially underpricing its M&A integration capability + FCF generation + deleveraging + AI/data optionality.
My current valuation framework:
Bear case: $32–36
Base fair value: $56–64, midpoint \~$60
Bull case: $72–90 if Domo integration works and ARR growth reaccelerates.
At \~$42, the base case implies roughly 40%+ upside, while $36–40 would offer a substantially better margin of safety.
The thesis can absolutely fail. Key risks are weak organic growth, Domo integration problems, excessive leverage, MOVEit litigation and AI disruption of legacy products.
PRGS is potentially a mispriced, high-FCF software roll-up. The key question is whether management can turn Domo into another cash-generating asset without breaking the balance sheet.
Not financial advice — this is my own research framework.